Abvc Biopharma IncABVC
ASignal's systematic analysis rates ABVC as Bearish.
Reflects the latest available analysis · analyzed Aug 20, 2026
The case on ABVC
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Debt-to-equity ratio of 0.21x indicates low leverage
- Free cash flow of $1.16M suggests some liquidity inflow
- Price near Bollinger Lower Band (0.826), indicating potential reversal support
- Negative operating cash flow of $-3.34M
- Negative return on equity (-87.78%) and return on assets (-29.01%)
- Current ratio of 0.12x and quick ratio of 0.04x signal severe liquidity risk
- MACD below signal line with negative histogram, indicating bearish momentum
- Price below both SMA20 and SMA50, confirming downtrend
- Extremely low gross, operating, and net margins (0.00%)
See the full verdict on ABVC
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ABVC
Most investors never get a second opinion, let alone several. ASignal runs ABVC past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.